• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗微生物药物耐药性、COVID-19 与过去和未来大流行之间的相互关系。

The interrelationships between antimicrobial resistance, COVID-19, past, and future pandemics.

机构信息

Saudi Electronic University, Department of Public Health, P. O. Box 93499, Riyadh 11673, Saudi Arabia.

出版信息

J Infect Public Health. 2021 Jan;14(1):53-60. doi: 10.1016/j.jiph.2020.10.018. Epub 2020 Dec 9.

DOI:10.1016/j.jiph.2020.10.018
PMID:33341485
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7831651/
Abstract

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 was first reported in Wuhan, China in December 2019 and is associated with high levels of morbidity and mortality. Various types of bacterial and fungal infections occur in patients with COVID-19 with some resistant to antimicrobials that are associated with significantly worse outcomes and deaths. Besides, antimicrobial-resistant (AMR) co-infections are responsible for clinically significant mortality in past pandemics. There is evidence to suggest that factors such as the proliferation of adulterated antimicrobials in some developing countries, international travels, issues with healthcare financing, use/misuse by humans, and in agricultural production and climate change are determinants of AMR at various levels of society. These complex interrelated determinants intersect with AMR in current and past pandemics and could amplify the potential of a future antimicrobial resistance pandemic. Therefore, global concerted interventions targeted at all levels of society to reduce the use/misuse of antimicrobials and disrupt these multifaceted, interrelated, and interdependent factors are urgently needed. This paper leverages prior research to describe complex major determinants of antimicrobial resistance and provides fresh insights into possible intervention strategies to tackle antimicrobial resistance including in the current and future pandemics.

摘要

由严重急性呼吸系统综合征冠状病毒 2 引起的 COVID-19 大流行于 2019 年 12 月在中国武汉首次报告,与高发病率和死亡率相关。COVID-19 患者会发生各种类型的细菌和真菌感染,其中一些对抗生素具有耐药性,这与明显更差的结果和死亡有关。此外,抗微生物药物耐药性(AMR)合并感染是过去大流行中导致临床显著死亡的原因。有证据表明,在一些发展中国家抗生素掺假的扩散、国际旅行、医疗保健融资问题、人类的使用/滥用以及农业生产和气候变化等因素是社会各层面 AMR 的决定因素。这些复杂的相互关联的决定因素与当前和过去大流行中的 AMR 相互交叉,并可能放大未来抗生素耐药性大流行的潜力。因此,迫切需要在社会各层面采取全球协同干预措施,以减少抗生素的使用/滥用,并打破这些多方面、相互关联和相互依存的因素。本文利用先前的研究来描述抗微生物药物耐药性的复杂主要决定因素,并提供对抗微生物药物耐药性的可能干预策略的新见解,包括在当前和未来的大流行中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e143/7831651/eed266b70b36/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e143/7831651/eed266b70b36/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e143/7831651/eed266b70b36/gr1_lrg.jpg

相似文献

1
The interrelationships between antimicrobial resistance, COVID-19, past, and future pandemics.抗微生物药物耐药性、COVID-19 与过去和未来大流行之间的相互关系。
J Infect Public Health. 2021 Jan;14(1):53-60. doi: 10.1016/j.jiph.2020.10.018. Epub 2020 Dec 9.
2
Multiple impacts of the COVID-19 pandemic and antimicrobial stewardship on antimicrobial resistance in nosocomial infections: an interrupted time series analysis.2019年冠状病毒病大流行和抗菌药物管理对医院感染中抗菌药物耐药性的多重影响:一项中断时间序列分析
Front Public Health. 2024 Jul 17;12:1419344. doi: 10.3389/fpubh.2024.1419344. eCollection 2024.
3
Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance.关于 COVID-19 大流行对抗菌药物耐药性研究和监测的潜在影响的关键考虑因素。
Trans R Soc Trop Med Hyg. 2021 Oct 1;115(10):1122-1129. doi: 10.1093/trstmh/trab048.
4
Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic.大流行后世界的抗菌药物耐药性研究:关于新冠疫情中抗菌药物耐药性研究的见解
J Glob Antimicrob Resist. 2021 Jun;25:5-7. doi: 10.1016/j.jgar.2021.02.013. Epub 2021 Mar 1.
5
Collateral damage of the COVID-19 pandemic: Exacerbation of antimicrobial resistance and disruptions to antimicrobial stewardship programmes?2019年冠状病毒病疫情的附带损害:抗菌药物耐药性加剧及抗菌药物管理计划受到干扰?
S Afr Med J. 2020 Jun 2;110(7):572-573. doi: 10.7196/SAMJ.2020.v110i7.14917.
6
Antimicrobial multidrug resistance in the era of COVID-19: a forgotten plight?COVID-19 时代的抗菌多药耐药性:被遗忘的困境?
Antimicrob Resist Infect Control. 2021 Jan 29;10(1):21. doi: 10.1186/s13756-021-00893-z.
7
How can lessons from the COVID-19 pandemic enhance antimicrobial resistance surveillance and stewardship?从 COVID-19 大流行中吸取的教训如何增强抗菌药物耐药性监测和管理?
Lancet Infect Dis. 2023 Aug;23(8):e301-e309. doi: 10.1016/S1473-3099(23)00124-X. Epub 2023 Jun 5.
8
Antimicrobial Resistance Threats in the emerging COVID-19 pandemic: Where do we stand?新冠疫情期间出现的抗菌药物耐药性威胁:我们处于何种境地?
J Infect Public Health. 2021 May;14(5):555-560. doi: 10.1016/j.jiph.2021.02.011. Epub 2021 Mar 5.
9
COVID-19 and antimicrobial stewardship: lessons learned, best practices, and future implications.COVID-19 与抗菌药物管理:经验教训、最佳实践和未来影响。
Int J Infect Dis. 2021 Dec;113:103-108. doi: 10.1016/j.ijid.2021.10.001. Epub 2021 Oct 5.
10
A parallel and silent emerging pandemic: Antimicrobial resistance (AMR) amid COVID-19 pandemic.平行且无声的新兴大流行:COVID-19 大流行期间的抗微生物药物耐药性(AMR)。
J Infect Public Health. 2023 Apr;16(4):611-617. doi: 10.1016/j.jiph.2023.02.021. Epub 2023 Feb 21.

引用本文的文献

1
Antimicrobial and Anti-Biofilm Activity of Dichlorophen-Functionalized Gold Nanoparticles Against Carbapenem-Resistant .二氯酚功能化金纳米颗粒对耐碳青霉烯类细菌的抗菌及抗生物膜活性
Int J Nanomedicine. 2025 Aug 25;20:10255-10277. doi: 10.2147/IJN.S532807. eCollection 2025.
2
Structural and Functional Effects of the Interaction Between an Antimicrobial Peptide and Its Analogs with Model Bacterial and Erythrocyte Membranes.抗菌肽及其类似物与模型细菌膜和红细胞膜相互作用的结构和功能效应
Biomolecules. 2025 Aug 7;15(8):1143. doi: 10.3390/biom15081143.
3
Invisible Engines of Resistance: How Global Inequities Drive Antimicrobial Failure.

本文引用的文献

1
Using for bioinspired synthesis of titanium dioxide and silver nanoparticles, targeting biomedical applications.用于二氧化钛和银纳米颗粒的仿生合成,目标是生物医学应用。
RSC Adv. 2020 Aug 28;10(53):32137-32147. doi: 10.1039/d0ra02637a. eCollection 2020 Aug 26.
2
Short-course versus long-course antibiotic treatment in patients with uncomplicated gram-negative bacteremia: A systematic review and meta-analysis.短程与长程抗生素治疗方案对单纯革兰阴性菌菌血症患者的影响:系统评价与荟萃分析。
J Clin Pharm Ther. 2021 Feb;46(1):173-180. doi: 10.1111/jcpt.13277. Epub 2020 Sep 27.
3
Secondary Bacterial Infections in Patients With Viral Pneumonia.
隐形的耐药引擎:全球不平等如何导致抗菌药物失效
Antibiotics (Basel). 2025 Jun 30;14(7):659. doi: 10.3390/antibiotics14070659.
4
Exploring Global Interest in Propolis, Nanosilver, and Biomaterials: Insights and Implications for Dentistry from Big Data Analytics.探索全球对蜂胶、纳米银和生物材料的兴趣:大数据分析对牙科的启示与影响
Dent J (Basel). 2025 Jun 6;13(6):253. doi: 10.3390/dj13060253.
5
Midkine (MDK) in cancer and drug resistance: from inflammation to therapy.癌症与耐药性中的中期因子(MDK):从炎症到治疗
Discov Oncol. 2025 Jun 11;16(1):1062. doi: 10.1007/s12672-025-02941-1.
6
Adaptation and validation of the scale for the prevention and control of healthcare-associated infections among nursing students: an exploratory factor analysis approach.护理专业学生医疗相关感染预防与控制量表的改编与验证:探索性因素分析方法
Front Public Health. 2025 Apr 25;13:1537811. doi: 10.3389/fpubh.2025.1537811. eCollection 2025.
7
Rebound of Antibiotic Use and Respiratory Infections After Resumption of Normalcy From COVID-19 in Hong Kong.香港从新冠疫情恢复正常后抗生素使用及呼吸道感染的反弹情况。
Infect Drug Resist. 2025 Mar 11;18:1325-1337. doi: 10.2147/IDR.S502126. eCollection 2025.
8
Multiple impacts of the COVID-19 pandemic and antimicrobial stewardship on antimicrobial resistance in nosocomial infections: an interrupted time series analysis.2019年冠状病毒病大流行和抗菌药物管理对医院感染中抗菌药物耐药性的多重影响:一项中断时间序列分析
Front Public Health. 2024 Jul 17;12:1419344. doi: 10.3389/fpubh.2024.1419344. eCollection 2024.
9
CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders.CRISPR/Cas9 基因编辑:一种治疗呼吸障碍药物耐药性的新策略。
Cell Commun Signal. 2024 Jun 14;22(1):329. doi: 10.1186/s12964-024-01713-8.
10
Prevalence, pandemic, preventions and policies to overcome antimicrobial resistance.抗菌药物耐药性的流行情况、大流行、预防措施及应对政策。
Saudi J Biol Sci. 2024 Aug;31(8):104032. doi: 10.1016/j.sjbs.2024.104032. Epub 2024 May 26.
病毒性肺炎患者的继发性细菌感染
Front Med (Lausanne). 2020 Aug 5;7:420. doi: 10.3389/fmed.2020.00420. eCollection 2020.
4
Co-infections: potentially lethal and unexplored in COVID-19.合并感染:在新冠病毒病中可能致命且未被探索。
Lancet Microbe. 2020 May;1(1):e11. doi: 10.1016/S2666-5247(20)30009-4. Epub 2020 Apr 24.
5
The Unrecognized Threat of Secondary Bacterial Infections with COVID-19.新冠病毒二次细菌性感染的未被识别威胁。
mBio. 2020 Aug 7;11(4):e01806-20. doi: 10.1128/mBio.01806-20.
6
COVID-19 and Clostridioides difficile infection (CDI): Possible implications for elderly patients.新型冠状病毒肺炎与艰难梭菌感染:对老年患者的潜在影响。
Anaerobe. 2020 Aug;64:102233. doi: 10.1016/j.anaerobe.2020.102233. Epub 2020 Jun 25.
7
Vaccines Against Antimicrobial Resistance.疫苗应对抗微生物药物耐药性
Front Immunol. 2020 Jun 3;11:1048. doi: 10.3389/fimmu.2020.01048. eCollection 2020.
8
SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19?SARS-CoV-2、细菌合并感染和 AMR:COVID-19 中的致命三联体?
EMBO Mol Med. 2020 Jul 7;12(7):e12560. doi: 10.15252/emmm.202012560. Epub 2020 Jun 15.
9
Covid-19 induced superimposed bacterial infection.新冠病毒感染引发的叠加细菌感染。
J Biomol Struct Dyn. 2021 Jul;39(11):4185-4191. doi: 10.1080/07391102.2020.1772110. Epub 2020 Jun 9.
10
Acquisition of multidrug-resistant Enterobacterales during international travel: a systematic review of clinical and microbiological characteristics and meta-analyses of risk factors.国际旅行期间获得耐多药肠杆菌科细菌:临床和微生物学特征的系统评价和危险因素的荟萃分析。
Antimicrob Resist Infect Control. 2020 May 20;9(1):71. doi: 10.1186/s13756-020-00733-6.